ADMA BIOLOGICS INC (ADMA) Stock News

USA - Nasdaq - NASDAQ:ADMA - US0008991046 - Common Stock

19.98 USD

+0.18 (+0.91%)

Last: 12/10/2025, 8:00:00 PM

19.895 USD

-0.09 (-0.43%)

Pre-Market: 12/11/2025, 8:55:59 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ADMA Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill

News Image

ADMA Biologics Inc (NASDAQ:ADMA) Emerges as a Top GARP Investment Candidate

6 days ago - By: Zacks Investment Research - Mentions: VRTX

Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?

7 days ago - By: Zacks Investment Research - Mentions: ZTS CRMD ARQT

Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know

8 days ago - By: Zacks Investment Research - Mentions: PCRX CRMD ARQT

PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain

8 days ago - By: Zacks Investment Research - Mentions: AZN CRMD ARQT

AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension

9 days ago - By: Zacks Investment Research - Mentions: CRMD MIRM ARQT

MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study

9 days ago - By: Zacks Investment Research - Mentions: JNJ CRMD ARQT

JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis

10 days ago - By: Zacks Investment Research - Mentions: ARCT CRMD ARQT

ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know

10 days ago - By: Zacks Investment Research

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

14 days ago - By: Zacks Investment Research

Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 60.24%: Read This Before Placing a Bet

16 days ago - By: Zacks Investment Research

Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know

20 days ago - By: Zacks Investment Research - Mentions: AZN MRK EDIT

AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo

21 days ago - By: Zacks Investment Research - Mentions: EDIT COGT ARQT

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

21 days ago - By: Zacks Investment Research - Mentions: GILD MRK ARQT

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

22 days ago - By: Zacks Investment Research - Mentions: NVO VNDA ARQT

VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects

23 days ago - By: Zacks Investment Research - Mentions: NVO ARQT VTYX

VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know

23 days ago - By: Zacks Investment Research - Mentions: GSK ALEC ARQT

Alector Stock Plummets 63% in a Month: Here's What You Need to Know

a month ago - By: Zacks Investment Research

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

a month ago - By: Zacks Investment Research - Mentions: ANIP KOD ARQT

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

a month ago - By: Zacks Investment Research - Mentions: NVS ANIP ARQT

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint

a month ago - By: Zacks Investment Research

Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?

a month ago - By: Zacks Investment Research

Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors

a month ago - By: Zacks Investment Research - Mentions: ANIP EDIT ARQT

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

a month ago - By: Zacks Investment Research

Wall Street Analysts Believe Adma Biologics (ADMA) Could Rally 108.5%: Here's is How to Trade

a month ago - By: Zacks Investment Research - Mentions: ATRA

Adma Biologics (ADMA) Q3 Earnings Match Estimates

a month ago - By: ADMA Biologics, Inc.

ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: ADMA Biologics, Inc.

ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

a month ago - By: The Motley Fool - Mentions: STRL SPXC MMYT ITRI

This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why

a month ago - By: Zacks Investment Research

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

a month ago - By: ADMA Biologics, Inc.

ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025

2 months ago - By: Zacks Investment Research

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

2 months ago - By: Zacks Investment Research

Adma Biologics (ADMA) Stock Moves -1.36%: What You Should Know

2 months ago - By: Zacks Investment Research

Why Adma Biologics (ADMA) Outpaced the Stock Market Today

3 months ago - By: Zacks Investment Research

Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note

3 months ago - By: Zacks Investment Research

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?